VRX Investor Deadline Alert: Law Offices of Howard G. Smith Reminds Valeant Pharmaceuticals, Inc. Investors of Upcoming Lead ...
November 20 2015 - 10:30AM
Business Wire
Law Offices of Howard G. Smith reminds investors of the upcoming
December 21, 2015 deadline to file a lead plaintiff motion
in the class action filed on behalf of a class (the “Class”) of
investors who purchased Valeant Pharmaceuticals, Inc. (“Valeant ”
or the “Company”) (NYSE:VRX) securities between February 28, 2014
and October 21, 2015 inclusive (the “Class Period”). Investors who
suffered losses of over $500,000 on their investment in Valeant
securities are encouraged to contact the Law Offices of Howard G.
Smith to discuss their legal rights.
The complaint alleges that the defendants issued false and
misleading statements to investors and/or failed to disclose that:
(1) Valeant had deficient internal controls, (2) Valeant had a
relationship with a network of specialty pharmacies used to boost
Valeant’s sales of its high-priced drugs, (3) the use of specialty
pharmacies left Valeant vulnerable to increased regulatory risks,
(4) Defendants were under government scrutiny for its financial
assistance programs for patients, pricing decisions and the
distribution of its products, (5) Valeant faced the risk of
scrutiny over its price increases, (6) without using specialty
pharmacies, Valeant’s financial performance would be negatively
impacted, (7) without using specialty pharmacies, Valeant’s Class
Period performance would have been negatively impacted, (8)
Valeant’s true relationship with Philidor and the extent of that
relationship, (9) Valeant controlled Philidor, (10) Valeant’s
subsidiary KGA had a secured lien interest on Philidor’s ownership,
(11) Defendants were engaged in a scheme to manipulate Valeant’s
stock price, and (12) as a result, Valeant’s public statements were
materially false and misleading and/or lacked a reasonable basis at
all relevant times. Over the course of several disclosures
revealing the grave regulatory risk facing the Company, Valeant
shares have declined sharply in value, thereby injuring
investors.
If you purchased shares of Valeant during the Class Period you
may move the Court no later than December 21, 2015 to ask
the Court to appoint you as lead plaintiff if you meet certain
legal requirements. To be a member of the Class you need not take
any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you
wish to learn more about this action, or if you have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by e-mail to
howardsmith@howardsmithlaw.com, or visit our website at
http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151120005179/en/
Law Offices of Howard G. SmithHoward G. Smith,
Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2023 to Apr 2024